Advertisement

Topics

Celgene Corporation and Agios Pharmaceuticals, Inc. Company Profile

14:30 EDT 23rd September 2018 | BioPortfolio


News Articles [1001 Associated News Articles listed on BioPortfolio]

Agios, Celgene End Collaboration to Develop Cancer Treatment AG-881

Agios Pharmaceuticals said it agreed with Celgene to end a three-year-old collaboration to develop and commercialize treatments containing its most advanced clinical cancer candidate AG-881 (vorasiden...

Celgene Vet Jackie Fouse Taking Over as CEO of Agios Pharmaceuticals; Companies Also Terminate Pr...

One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Agios gets to prove its marketing abilities with new approval

The biotech expects that its time helping Celgene roll out Idhifa will benefit the commercialization of Tibsovo, Agios' first wholly-owned product.

After a High-Speed Decade, Agios CEO David Schenkein to Step Aside

David Schenkein, the longtime CEO of Agios Pharmaceuticals, will step aside next year after transforming what was once a high-risk Cambridge, MA-based startup into a public biotech with over 500 emplo...

FDA Grants Approval of Agios’ Pharmaceuticals’ TIBSOVO®

Agios Pharmaceuticals (NASDAQ:AGIO) has announced that TIBSOVO was granted approval from the US Food and Drug Administration (FDA) for treatment of adult patients with relapsed or refractory acute mye...

Agios, CStone collaborate on ivosidenib R&D

Agios Pharmaceuticals entered into a licensing deal with CStone Pharmaceuticals for the development and commercialization of  -More- 

Agios' AML therapy wins FDA nod

Agios Pharmaceuticals' Tibsovo, or ivosidenib, was approved by the FDA as a treatment for adult patients with relapsed or ref -More- 

PubMed Articles [144 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

Effects of pharmaceuticals on microbial communities and activity of soil enzymes in mesocosm-scale constructed wetlands.

Cyperus alternifolius based mesocosm-scale constructed wetland was employed to remove pharmaceuticals. We investigated the microbial community composition using phosphor lipid fatty acids (PFLAs) anal...

Clinical Trials [232 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1521 Associated Companies listed on BioPortfolio]

Agios Pharmaceuticals, Inc.

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Agios has ...

Celgene Corporation and Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals , Inc.

Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadersh...

Agios Pharmaceuticals

Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism. To suppor...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Celgene Corporation and Agios Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Celgene Corporation and Agios Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Celgene Corporation and Agios Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Celgene Corporation and Agios Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celgene Corporation and Agios Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Celgene Corporation and Agios Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record